-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Medical Network, July 5 News On July 1, Tianyao shares announced that its subsidiary Tianjin Jinyao Pharmaceutical's methylprednisolone sodium succinate (40mg specification) for injection was approved as a supplementary application
.
Prior to this, Tianjin Jinyao Pharmaceutical's methylprednisolone sodium succinate for injection has been approved for 4 specifications, of which the 1.
0g and 2.
0g specifications were the first to be reviewed
.
According to data from Meinenet, in 2020, the sales of methylprednisolone sodium succinate for terminal injection in public medical institutions in China will be close to 2 billion yuan
.
.
Prior to this, Tianjin Jinyao Pharmaceutical's methylprednisolone sodium succinate for injection has been approved for 4 specifications, of which the 1.
0g and 2.
0g specifications were the first to be reviewed
.
According to data from Meinenet, in 2020, the sales of methylprednisolone sodium succinate for terminal injection in public medical institutions in China will be close to 2 billion yuan
.
Drug- related situation
Methylprednisolone sodium succinate for injection is a glucocorticoid drug, mainly used for anti-inflammatory therapy, immunosuppressive therapy, treatment of blood diseases and tumors , treatment of shock, etc.
The original manufacturer of this product is Pfizer
.
The original manufacturer of this product is Pfizer
.
Source: One-click search on Mi Nei.
com
com
According to data from Meinenet, in 2020, the sales of methylprednisolone sodium succinate for terminal injection in China's urban public hospitals , county-level public hospitals, urban community centers, and township health centers (Chinese public medical institutions) will be nearly 2 billion yuan
.
At present, the injection of methylprednisolone sodium succinate production enterprises have nine, where Pfizer has the largest share, accounting for more than 45%, Rongsheng Pharmaceutical Medicines and Pharmaceutical Tianjin Jin-yao respectively in second and third
.
.
At present, the injection of methylprednisolone sodium succinate production enterprises have nine, where Pfizer has the largest share, accounting for more than 45%, Rongsheng Pharmaceutical Medicines and Pharmaceutical Tianjin Jin-yao respectively in second and third
.
Source: Meinenet MED2.
0 Chinese Drug Evaluation Database
0 Chinese Drug Evaluation Database
At present, four companies including Sinopharm Rongsheng Pharmaceutical, Tianjin Jinyao Pharmaceutical, Liaoning Haisco Pharmaceutical, and Chongqing Huabang Pharmaceutical have been approved as supplementary applications for sodium methylprednisolone succinate for injection
.
Among them, Tianjin Jinyao Pharmaceutical Co.
, Ltd.
has been approved for 4 specifications before.
The 1.
0g and 2.
0g specifications are the first to be reviewed, the 500mg specification is the second, and the 125mg specification is the third.
The 40mg specification approved this time is the third company to have reviewed it
.
.
Among them, Tianjin Jinyao Pharmaceutical Co.
, Ltd.
has been approved for 4 specifications before.
The 1.
0g and 2.
0g specifications are the first to be reviewed, the 500mg specification is the second, and the 125mg specification is the third.
The 40mg specification approved this time is the third company to have reviewed it
.
Tianyao said that the consistency evaluation of methylprednisolone sodium succinate for injection is beneficial to enhance the company's market competitiveness of the drug, and at the same time, it has accumulated experience for the company's subsequent product consistency evaluation work
.
Up to now, the company has invested about 10 million yuan in research and development projects for the consistency evaluation of methylprednisolone sodium succinate for injection (40mg specification), and has invested in research and development projects for all specifications of methylprednisolone sodium succinate for injection.
The cost is about 31 million yuan
.
.
Up to now, the company has invested about 10 million yuan in research and development projects for the consistency evaluation of methylprednisolone sodium succinate for injection (40mg specification), and has invested in research and development projects for all specifications of methylprednisolone sodium succinate for injection.
The cost is about 31 million yuan
.
Source: Listed company announcements, Mi Nei.
com database
com database
Medical Network, July 5 News On July 1, Tianyao shares announced that its subsidiary Tianjin Jinyao Pharmaceutical's methylprednisolone sodium succinate (40mg specification) for injection was approved as a supplementary application
.
Prior to this, Tianjin Jinyao Pharmaceutical's methylprednisolone sodium succinate for injection has been approved for 4 specifications, of which the 1.
0g and 2.
0g specifications were the first to be reviewed
.
According to data from Meinenet, in 2020, the sales of methylprednisolone sodium succinate for terminal injection in public medical institutions in China will be close to 2 billion yuan
.
.
Prior to this, Tianjin Jinyao Pharmaceutical's methylprednisolone sodium succinate for injection has been approved for 4 specifications, of which the 1.
0g and 2.
0g specifications were the first to be reviewed
.
According to data from Meinenet, in 2020, the sales of methylprednisolone sodium succinate for terminal injection in public medical institutions in China will be close to 2 billion yuan
.
Drug- related situation
Methylprednisolone sodium succinate for injection is a glucocorticoid drug, mainly used for anti-inflammatory therapy, immunosuppressive therapy, treatment of blood diseases and tumors , treatment of shock, etc.
The original manufacturer of this product is Pfizer
.
The original manufacturer of this product is Pfizer
.
Source: One-click search on Mi Nei.
com
com
According to data from Meinenet, in 2020, the sales of methylprednisolone sodium succinate for terminal injection in China's urban public hospitals , county-level public hospitals, urban community centers, and township health centers (Chinese public medical institutions) will be nearly 2 billion yuan
.
At present, the injection of methylprednisolone sodium succinate production enterprises have nine, where Pfizer has the largest share, accounting for more than 45%, Rongsheng Pharmaceutical Medicines and Pharmaceutical Tianjin Jin-yao respectively in second and third
.
.
At present, the injection of methylprednisolone sodium succinate production enterprises have nine, where Pfizer has the largest share, accounting for more than 45%, Rongsheng Pharmaceutical Medicines and Pharmaceutical Tianjin Jin-yao respectively in second and third
.
Source: Meinenet MED2.
0 Chinese Drug Evaluation Database
0 Chinese Drug Evaluation Database
At present, four companies including Sinopharm Rongsheng Pharmaceutical, Tianjin Jinyao Pharmaceutical, Liaoning Haisco Pharmaceutical, and Chongqing Huabang Pharmaceutical have been approved as supplementary applications for sodium methylprednisolone succinate for injection
.
Among them, Tianjin Jinyao Pharmaceutical Co.
, Ltd.
has been approved for 4 specifications before.
The 1.
0g and 2.
0g specifications are the first to be reviewed, the 500mg specification is the second, and the 125mg specification is the third.
The 40mg specification approved this time is the third company to have reviewed it
.
.
Among them, Tianjin Jinyao Pharmaceutical Co.
, Ltd.
has been approved for 4 specifications before.
The 1.
0g and 2.
0g specifications are the first to be reviewed, the 500mg specification is the second, and the 125mg specification is the third.
The 40mg specification approved this time is the third company to have reviewed it
.
Tianyao said that the consistency evaluation of methylprednisolone sodium succinate for injection is beneficial to enhance the company's market competitiveness of the drug, and at the same time, it has accumulated experience for the company's subsequent product consistency evaluation work
.
Up to now, the company has invested about 10 million yuan in research and development projects for the consistency evaluation of methylprednisolone sodium succinate for injection (40mg specification), and has invested in research and development projects for all specifications of methylprednisolone sodium succinate for injection.
The cost is about 31 million yuan
.
.
Up to now, the company has invested about 10 million yuan in research and development projects for the consistency evaluation of methylprednisolone sodium succinate for injection (40mg specification), and has invested in research and development projects for all specifications of methylprednisolone sodium succinate for injection.
The cost is about 31 million yuan
.
Source: Listed company announcements, Mi Nei.
com database
com database
Medical Network, July 5 News On July 1, Tianyao shares announced that its subsidiary Tianjin Jinyao Pharmaceutical's methylprednisolone sodium succinate (40mg specification) for injection was approved as a supplementary application
.
Prior to this, Tianjin Jinyao Pharmaceutical's methylprednisolone sodium succinate for injection has been approved for 4 specifications, of which the 1.
0g and 2.
0g specifications were the first to be reviewed
.
According to data from Meinenet, in 2020, the sales of methylprednisolone sodium succinate for terminal injection in public medical institutions in China will be close to 2 billion yuan
.
.
Prior to this, Tianjin Jinyao Pharmaceutical's methylprednisolone sodium succinate for injection has been approved for 4 specifications, of which the 1.
0g and 2.
0g specifications were the first to be reviewed
.
According to data from Meinenet, in 2020, the sales of methylprednisolone sodium succinate for terminal injection in public medical institutions in China will be close to 2 billion yuan
.
Drug- related situation
Medicine, medicine, medicine Methylprednisolone sodium succinate for injection is a glucocorticoid drug, mainly used for anti-inflammatory therapy, immunosuppressive therapy, treatment of blood diseases and tumors , treatment of shock, etc.
The original manufacturer of this product is Pfizer
.
Disease disease disease tumor tumor tumorThe original manufacturer of this product is Pfizer
.
Source: One-click search on Mi Nei.
com
com
According to data from Meinenet, in 2020, the sales of methylprednisolone sodium succinate for terminal injection in China's urban public hospitals , county-level public hospitals, urban community centers, and township health centers (Chinese public medical institutions) will be nearly 2 billion yuan
.
At present, the injection of methylprednisolone sodium succinate production enterprises have nine, where Pfizer has the largest share, accounting for more than 45%, Rongsheng Pharmaceutical Medicines and Pharmaceutical Tianjin Jin-yao respectively in second and third
.
Hospital Hospital Hospital Enterprise Enterprise Enterprise.
At present, the injection of methylprednisolone sodium succinate production enterprises have nine, where Pfizer has the largest share, accounting for more than 45%, Rongsheng Pharmaceutical Medicines and Pharmaceutical Tianjin Jin-yao respectively in second and third
.
Source: Meinenet MED2.
0 Chinese Drug Evaluation Database
0 Chinese Drug Evaluation Database
At present, four companies including Sinopharm Rongsheng Pharmaceutical, Tianjin Jinyao Pharmaceutical, Liaoning Haisco Pharmaceutical, and Chongqing Huabang Pharmaceutical have been approved as supplementary applications for sodium methylprednisolone succinate for injection
.
Among them, Tianjin Jinyao Pharmaceutical Co.
, Ltd.
has been approved for 4 specifications before.
The 1.
0g and 2.
0g specifications are the first to be reviewed, the 500mg specification is the second, and the 125mg specification is the third.
The 40mg specification approved this time is the third company to have reviewed it
.
.
Among them, Tianjin Jinyao Pharmaceutical Co.
, Ltd.
has been approved for 4 specifications before.
The 1.
0g and 2.
0g specifications are the first to be reviewed, the 500mg specification is the second, and the 125mg specification is the third.
The 40mg specification approved this time is the third company to have reviewed it
.
Tianyao said that the consistency evaluation of methylprednisolone sodium succinate for injection is beneficial to enhance the company's market competitiveness of the drug, and at the same time, it has accumulated experience for the company's subsequent product consistency evaluation work
.
Up to now, the company has invested about 10 million yuan in research and development projects for the consistency evaluation of methylprednisolone sodium succinate for injection (40mg specification), and has invested in research and development projects for all specifications of methylprednisolone sodium succinate for injection.
The cost is about 31 million yuan
.
.
Up to now, the company has invested about 10 million yuan in research and development projects for the consistency evaluation of methylprednisolone sodium succinate for injection (40mg specification), and has invested in research and development projects for all specifications of methylprednisolone sodium succinate for injection.
The cost is about 31 million yuan
.
Source: Listed company announcements, Mi Nei.
com database
com database
